Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV-1 pseudovirion vaccine
- Development stage
- Discontinued
- Lead developer
- Immuno
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The HIV-1 pseudovirion vaccine is an experimental virus-like particle (VLP) candidate developed for the prevention and treatment of HIV-1 infection. These pseudovirions are non-infectious, replication-incompetent particles produced in vitro using mammalian cell expression systems (such as Vero cells). The vaccine mimics the structural morphology of the wild-type HIV-1 virus but lacks the viral genome. It incorporates key structural proteins, specifically the **Gag protein** (providing the core structure) and the **Envelope glycoprotein gp160** (displayed on the surface), to elicit broad immune responses. This dual-antigen approach is designed to trigger both humoral immunity (producing neutralizing antibodies against the envelope) and cellular immunity (activating T-cell responses against internal Gag proteins). Historically evaluated in early clinical trials such as ACTG 256, the vaccine was often paired with adjuvants like alum or QS21 to enhance immunogenicity.
- Other names
- HIV-1 pseudovirion (gp160/p24)Immuno AG HIV-1 VLPp24/gp160 pseudovirion vaccine
02
Targets
Env (HIV-1 envelope glycoprotein)Gag (HIV-1 Gag polyprotein)
Beyond the preview
Go deeper on HIV-1 pseudovirion vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV-1 pseudovirion vaccine.